GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Patients Request Cell Quality Records?

Yes. You can ask your clinic for the quality records covering the cells intended for your treatment. Start with a batch-specific certificate of analysis or quality-control summary. Ask for the batch or sample ID, tests and methods, sampling dates, results, final-or-pending status, and release authorisation. Making a request does not guarantee access to the complete manufacturing file; what you can obtain depends on the applicable law, setting, and records held by the provider.

In a 2018 US investigation of non-approved cord-blood products used for non-hematopoietic conditions, CDC counted 12 infected patients across three states. All 12 went to hospital, with first stays of 4 to 58 days. Bacteria turned up in unopened vials too, and the distributor recalled the product on 28 September 2018. Mm6750a5.htm

Can Patients Request Cell Quality Records?

What to request by name

Ask which of the following records are available for your treatment. Document names and contents vary, so describe the information you need rather than relying on a title alone.

Document What it shows
Certificate of analysis or QC summary The tests, methods, and results for your batch or sample.
Batch or processing record How the batch was handled: source material, culture steps, dates, and who signed it off.
Sterility and contamination checks Tests that look for microbes. Mycoplasma testing stands apart from general bacterial and fungal testing because mycoplasma is hard to catch by routine means.
Cell checks Cell count measures quantity; viability estimates the proportion of living cells under the test conditions. Identity testing addresses what the cells are. A high viability result alone does not establish identity, potency, or clinical benefit.
Donor-related screening For donor-derived (allogeneic) cells, ask what donor eligibility and infectious-disease screening apply, and whether a non-identifying summary is available.
Release decision The decision authorising use of the batch, the applicable release criteria, and any results still pending at that time. Ask about deviations or exceptions rather than assuming release means every result was final.

Why your batch record matters

A batch record helps connect the material intended for you with its test results and release decision. Ask which criteria apply and whether the results met them. These records address aspects of product quality, not whether the treatment will help your particular condition. The CDC outbreak illustrates contamination risk; it does not show how often contamination occurs across clinics.

Looks can fool you, so ask for the mycoplasma line in particular. Guidance from the University of North Carolina’s Tissue Culture Facility describes mycoplasmas as wall-less bacteria just 0.2 to 0.3 microns across. They can hit 10 million to 100 million organisms per millilitre in mammalian cultures, yet you will not see them under a regular light microscope. Most routine culture antibiotics do not stop them either. Mycoplasmacontam This guidance covers research cultures, not any patient’s batch standard. Still, it shows why a dedicated mycoplasma check is a separate matter from routine bacterial testing. A clean-looking preparation proves nothing on looks alone.

A negative result means nothing turned up in the tested sample under that assay’s conditions. It does not prove the whole batch is clean. It says nothing about identity, potency, or likely benefit on its own. Each check answers only its own question.

How to ask

Put your request in writing before you commit to treatment or make a non-refundable payment. Ask what is available now, what will become available after processing, and who handles record requests. A report for cells that have not yet been prepared cannot contain completed batch results.

Questions to ask

  • Which quality report covers the cells for my procedure?
  • How does the sample ID on the report link to my cells?
  • When was the sample taken? Does it cover steps done after sampling?
  • Which methods did you use for sterility, mycoplasma, and other microbe checks?
  • Is each result final, or will some arrive after my procedure date?
  • Who ran the tests, and who signed the release?
  • If a result comes back positive, unclear, or missing, what happens to my batch and my appointment?

If you hear something vague like “we test everything,” push back gently. Ask for the explanation tied to your batch.

A paperwork scenario

Suppose a clinic sends a document showing a facility name and a treatment-plan number, but no batch identifier. That is a hypothetical example, not a patient case. Ask: “Which batch is intended for my procedure, and where is the report linking that batch to its test results?” If the clinic uses a coded identifier, ask it to explain the link without disclosing anyone else’s information.

Please provide the quality-control summary for the cells intended for my procedure, including the batch identifier, tests and methods, sampling dates, acceptance criteria, results, pending tests, and release authorisation. If the batch is not ready yet, please explain when these details will be available. If any record cannot be shared, please explain why and whether a redacted copy or summary is available.

What may be shared

A batch summary, a redacted report, and a complete manufacturing record are different requests. Ask the provider to identify which documents it holds and which it can disclose. Do not assume that receiving a summary means you have received every record you may be entitled to access.

Privacy and disclosure limits

Separate the information you need from information that may require additional safeguards or a different access process:

  • Donor or other patients’ information: request relevant screening conclusions without unnecessary personal identifiers.
  • Manufacturing and internal records: ask which details can be shared and which legal basis applies to any refusal. Confidentiality should not simply be assumed to settle your access rights.
  • Other batches: ask whether a report concerns your batch, a validation study, or a demonstration sample. Another batch’s passing result is not your batch’s result.

This is a practical request guide, not a determination of your legal entitlement to particular documents. For a disputed refusal, use the provider’s formal records-access process and seek advice appropriate to that jurisdiction.

How to ask in Japan

In Japan, distinguish product approval from the treatment-plan framework. The Pharmaceuticals and Medical Devices Agency (PMDA) publishes approval information for regenerative medical products. 0003 Separately, the Act on the Safety of Regenerative Medicine provides a framework involving provision plans, certified committee review, and requirements for cell-processing facilities. Index

A filed plan number, a committee opinion, or a facility licence tells you where a treatment stands in the system. It is not your batch result. It does not prove the treatment works for your disease. So ask which release checks apply to your batch, full stop. Consent forms should lay out the plan, its risks, other options, costs, and follow-up. But a signature on that form never makes a treatment effective or right for you.

What to check in the United States

Ask for the exact product name and its regulatory status as well as the batch record. FDA’s list identifies licensed cellular and gene therapy products by product and manufacturer; the applicable indication must also be checked in the product’s approval information. A licence is not blanket approval for other cell preparations or uses. Approved cellular and gene therapy products

A private clinic’s offer is not itself a regulatory category or an exemption. FDA warns that listing a study on ClinicalTrials.gov, or registering a firm and listing its product with FDA, does not mean that the product is legally marketed. Ask the clinician to explain the applicable regulatory pathway rather than accepting “registered” as an answer. Important patient and consumer information about regenerative medicine therapies Trial registration alone does not establish clinical benefit, and PubMed inclusion alone does not establish evidence quality. An approved therapy, an experimental intervention, and a privately offered service should not be treated as interchangeable.

How to read your summary

When you get the summary you requested, treat it as a checking aid. It is not an approval stamp:

  1. Linkage: does the batch or sample identifier connect to your treatment record? A matching preparation date alone is not a unique identifier. Ask for an explanation of any mismatch.
  2. Timing: when was each sample taken relative to processing, storage, transport, and administration? Testing before a later handling step cannot rule out contamination introduced during that step.
  3. Method: which method sat behind each check? Methods catch bugs in different ways, and each has blind spots. Ask if the lab sees the method as a fit for your material.
  4. Status: is each result final, and did it meet the stated acceptance criteria? If results will arrive after your procedure, ask why release is permitted, what uncertainty remains, and how a later positive result would be handled. A pending result is not a negative result.
  5. Responsibility: which lab did the work, and who made the release call? A result with no named reviewer behind it is hard to trust.

Missing paperwork is never a pass. If the report you requested is missing or hard to follow, ask your clinician and the lab in writing. If the answer still does not add up, get an independent medical opinion before you go ahead.

What to do if the clinic says no

Ask whether the record does not yet exist, is held by a separate laboratory or manufacturer, or is being withheld. Request the reason and any expected availability date in writing. Ask whether your doctor can document the release basis in your medical record. If the explanation remains unclear, use the formal access or complaints process and consider an independent medical opinion before proceeding with an elective intervention.

For trial offers, get the protocol ID, the ethics approval, and the registration details too. Confirm the site and check that you actually qualify.

Need help preparing a records request? Contact the patient support team with a general question. This is not a medical consultation; confirm privacy arrangements before sharing identifiable health records.

Contact us

Bottom line

Yes, you can request cell quality records. Ask early for a report linked to your batch, with methods, dates, acceptance criteria, results, pending tests, and release authorisation. Clarify what can be supplied and use the relevant access process if disclosure is disputed. Even a satisfactory quality report does not establish that an intervention is approved, effective for your condition, or suitable for you.

References

  1. Perkins KM et al. Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood-Derived Stem Cell Products for Other Than Hematopoietic or Immunologic Reconstitution, United States, 2018. MMWR Morb Mortal Wkly Rep 2018;67(50):1397-1399. Available at: https://www.cdc.gov/mmwr/volumes/67/wr/mm6750a5.htm
  2. University of North Carolina Lineberger Comprehensive Cancer Center, Tissue Culture Facility. Mycoplasma contamination guidance. Available at: https://unclineberger.org/tissueculture/contaminant/mycoplasmacontam/
  3. Pharmaceuticals and Medical Devices Agency (PMDA). Approved regenerative medical product information. Available at: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0003.html
  4. Ministry of Health, Labour and Welfare (MHLW). Regenerative medicine portal under the Act on the Safety of Regenerative Medicine. Available at: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/index.html
  5. U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
  6. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Available at: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies

This article is for general information only and is not medical advice. Cell-based interventions carry risks and uncertain benefits that depend on the disease, cell type, and how cells are prepared and given. Discuss your own situation with a qualified clinician.